Apr 28, 2017 by Motley Fool StaffIs Remicade Losing Out to Biosimilars?Biosimilars begin to take a small bite out of Johnson & Johnson's top line.
Apr 28, 2017 by Motley Fool StaffShould You Buy in a Bull Market?The stock market is probably a bit overvalued today. Should investors wait for a correction before buying in?
Apr 27, 2017 by Motley Fool StaffHere's How Fracking WorksOur energy analysts explain the ins and outs of one of the newer and more complicated ways producers are getting oil out of the ground.
Apr 27, 2017 by Motley Fool StaffWhat's Happening With Johnson & Johnson's Pharmaceuticals Business?These drugs were the company's biggest winners and losers last quarter.
Apr 26, 2017 by Motley Fool StaffHow Can a Company Be Cash-Flow-Negative, but Still Profitable?Listener Seth wants to know specifically how Netflix is in what sounds like a contradictory financial position.
Apr 26, 2017 by Motley Fool StaffThe Sudden Departure of Klaus Kleinfeld From ArconicIts CEO is on his way out after allegations of threats. Here's the context and what will probably happen next for Arconic.
Apr 26, 2017 by Motley Fool StaffWhy Facebook Is All-In on Augmented RealityCEO Mark Zuckerberg said augmented reality will be the social media giant’s "second act."
Apr 26, 2017 by Motley Fool StaffJohnson & Johnson's Medical Device Business: What Investors Need to KnowWhich medical devices did best and worst for the company last quarter?
Apr 25, 2017 by Motley Fool StaffWhy Does Everyone Keep Calling Tesla a "Car Company"?As listener Brian points out, given that it's a business with a diverse set of products, it's odd that the media and the market only want to compare it to Detroit's giants.
Apr 25, 2017 by Motley Fool StaffIBM's Declining Revenue Gives Mr. Market Big BluesDespite an earnings beat, IBM shares slumped in light of its 20th straight quarter of lower total revenue.
Apr 24, 2017 by Motley Fool StaffWant a Nintendo Switch Now? Expect to Pay UpThe video game industry has some big things happening. Here's what investors need to watch in 2017.
Apr 24, 2017 by Motley Fool StaffWhy Was Wells Fargo Left in the Dust Last Quarter?Wells Fargo was the only megabank to see its earnings fall in the first quarter of this year.
Apr 23, 2017 by Motley Fool StaffWhy Aren’t Higher Interest Rates Helping Citigroup?Despite higher interest rates, Citigroup’s net interest margin fell in the first quarter.
Apr 22, 2017 by Motley Fool StaffBank Earnings Are Off to a Great StartDon’t let falling bank stocks fool you. It was a very good quarter for the nation’s largest lenders.
Apr 21, 2017 by Motley Fool StaffThe Perils of the Trump BumpWhile Trump’s unexpected victory in the presidential election has caused bank stocks to soar, it has also caused valuations in the industry to diverge from the fundamentals.
Apr 21, 2017 by Motley Fool StaffEarnings Anticipation: Verizon, Zillow and Ellie Mae Need Good NewsSome changes and evolutionary pressures are likely to make these companies' quarterly reports interesting reading.
Apr 21, 2017 by Motley Fool StaffEarnings Anticipation: The Fools Can’t Wait to Hear From Visa, Mastercard, Snap and ChipotleSome changes and evolutionary pressures are likely to make these companies' quarterly reports interesting reading.
Apr 19, 2017 by Motley Fool StaffWhy Flexion Therapeutics' New Pain Drug Could Be a Game-ChangerZilretta could win FDA approval in knee pain later this year, and, if so, it could become the new standard of care.
Apr 19, 2017 by Motley Fool StaffHow Nektar Therapeutics' Latest Drug Could Shake Up the Market for Pain MedicineNKTR-181's ability to tackle back pain potentially positions it for an FDA application for approval.
Apr 19, 2017 by Motley Fool StaffIs Cara Therapeutics About to Change How We Treat Pain?The company's CR845 is about to enter late-stage studies as an alternative to opioids.
